BioSpace News Archive

Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net proceeds of $13.9 million, after deducting placement agents’ fees but before expenses payable by the Company.

TMR’s report on the global warts therapeutics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030.

With the tremendous rise in the prevalence of cancer across the world, the global market for cancer diagnostics is witnessing a remarkable surge in its size.

Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways, today announced the forthcoming oral presentation of preclinical data on selective adenosine A 2B receptor antagonist TT-702, at the American Association for Cancer Research (AACR) Annual Meeting

This Nature Biomedical Engineering publication demonstrates that Cardea’s new CRISPR-powered transistors, dubbed “SNP-Chip,” has the power to enable a new generation of genetics testing that will democratize genetics by removing the need for a lab.

- Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Cyril Konto , M.D., to the new position of Chief Medical Officer (CMO), effective immediately.

MDimune Inc. and Evercyte GmbH announced a strategic collaboration to develop tumor-targeted drug delivery by combining MDimune’s BioDrone® platform technology based on cell-derived vesicles (CDVs) and Evercyte’s technology to modify surface proteins to create tumor-specific binding affinity.

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.

HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021. As discussed during HTG’s earnings conference call on March 25, the company believes its full year 2021 revenue could grow 30% to 40% over 2020 levels as it navigates a resurgence of COVID-19, which impacted the first quarter

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that management will participate in a fireside chat at Cowen’s 2 nd Annual Consumer Platforms for the Next Generation Summit